SG11201911841PA - Topical formulations comprising montelukast and combinations with mussel adhesive proteins - Google Patents
Topical formulations comprising montelukast and combinations with mussel adhesive proteinsInfo
- Publication number
- SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA
- Authority
- SG
- Singapore
- Prior art keywords
- montelukast
- combinations
- topical formulations
- mussel adhesive
- adhesive proteins
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 108010004563 mussel adhesive protein Proteins 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017091819 | 2017-07-05 | ||
| CN2018087058 | 2018-05-16 | ||
| PCT/CN2018/094441 WO2019007356A1 (en) | 2017-07-05 | 2018-07-04 | TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911841PA true SG11201911841PA (en) | 2020-01-30 |
Family
ID=64949737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911841PA SG11201911841PA (en) | 2017-07-05 | 2018-07-04 | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11672792B2 (es) |
| EP (1) | EP3648767A4 (es) |
| JP (1) | JP7288404B2 (es) |
| KR (1) | KR20200039677A (es) |
| CN (3) | CN113491696A (es) |
| AU (1) | AU2018295944B2 (es) |
| CA (1) | CA3068818A1 (es) |
| MA (1) | MA52924A (es) |
| MX (1) | MX2020000029A (es) |
| SG (1) | SG11201911841PA (es) |
| TW (1) | TW201919633A (es) |
| WO (1) | WO2019007356A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200039677A (ko) * | 2017-07-05 | 2020-04-16 | 장인 무코케어 파마슈티컬 컴퍼니 리미티드 | 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형 |
| CA3112420A1 (en) | 2018-09-14 | 2020-03-19 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates of montelukast and peptides |
| CN113613657A (zh) * | 2019-01-10 | 2021-11-05 | 江阴优培尔康药业有限公司 | 含有白三烯受体拮抗剂的新型配制品 |
| AU2020344762A1 (en) * | 2019-09-14 | 2022-04-14 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptides |
| EP4069713A1 (en) * | 2019-12-02 | 2022-10-12 | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | New conjugates of peptides and polysaccharide |
| KR20220119051A (ko) * | 2019-12-02 | 2022-08-26 | 엔리티사 (상하이) 파마슈티컬 컴퍼니 리미티드 | 신규한 다기능성 올리고펩타이드 |
| JP7314421B2 (ja) | 2020-02-03 | 2023-07-25 | タロー・ファーマシューティカル・インダストリーズ・リミテッド | 局所用モンテルカスト製剤 |
| EP4228641A1 (en) | 2020-10-13 | 2023-08-23 | Diomed Developments Limited | Gel formulations comprising montelukast |
| CN114588267A (zh) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | 一种含酰胺类局部麻醉药的药物组合物 |
| WO2022193185A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| AU2022323492A1 (en) * | 2021-08-06 | 2024-03-21 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New treatment of immunodeficiency disorder |
| CN116421547A (zh) * | 2023-03-09 | 2023-07-14 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU224814B1 (en) * | 1995-12-28 | 2006-02-28 | Mitsubishi Pharma Corp | Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases |
| US20030207932A1 (en) * | 2002-05-03 | 2003-11-06 | Morris Mann | Compositions that prevent post-traumatic hyperpigmentation and methods related thereto |
| WO2005013885A2 (en) * | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| US6987170B1 (en) * | 2004-08-09 | 2006-01-17 | Battelle Energy Alliance, Llc | Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis |
| WO2007126865A2 (en) | 2006-03-30 | 2007-11-08 | Patrin Pharma | Leukotriene antagonists via nasal drug delivery |
| CN1961867A (zh) * | 2006-11-16 | 2007-05-16 | 徐英权 | 孟鲁司特钠的颗粒剂型 |
| WO2008106081A1 (en) * | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation |
| WO2008105803A1 (en) * | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and uses thereof |
| US20110124681A1 (en) * | 2008-05-06 | 2011-05-26 | Schlesinger Larry S | Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| GB0915319D0 (en) | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
| CN101773503A (zh) * | 2010-01-12 | 2010-07-14 | 北京华禧联合科技发展有限公司 | 一种白三烯拮抗剂和抗组胺药组合物 |
| KR101801864B1 (ko) | 2010-06-16 | 2017-11-27 | 인플래머토리 리스폰스 리서치, 아이엔씨. | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| CN102895661A (zh) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| WO2013100564A1 (ko) | 2011-12-26 | 2013-07-04 | 에스케이케미칼 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름 |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| EP2969002B8 (en) * | 2013-03-13 | 2018-02-21 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN103655497B (zh) * | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | 一种孟鲁司特钠口腔崩解片及其制备方法 |
| CN105769825A (zh) | 2014-12-24 | 2016-07-20 | 广州朗圣药业有限公司 | 一种孟鲁司特钠的口腔膜剂及其制备方法 |
| CN105878215A (zh) | 2014-12-31 | 2016-08-24 | 天津康鸿医药科技发展有限公司 | 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途 |
| KR101892340B1 (ko) * | 2015-03-13 | 2018-08-27 | 경희대학교 산학협력단 | 몬테루카스트의 생체이용률을 개선시키기 위한 방법 |
| CN104784157B (zh) | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
| US10568938B2 (en) * | 2015-07-20 | 2020-02-25 | Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd. | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
| WO2017011983A1 (zh) * | 2015-07-20 | 2017-01-26 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 |
| US10548837B1 (en) | 2016-05-04 | 2020-02-04 | Taro Pharmaceutical Industries Ltd. | Topical montelukast for treatment of atopic dermatitis |
| KR20200039677A (ko) * | 2017-07-05 | 2020-04-16 | 장인 무코케어 파마슈티컬 컴퍼니 리미티드 | 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형 |
| MA52794A (fr) * | 2018-05-28 | 2021-04-14 | Jiangyin Usun Pharmaceutical Co Ltd | Nouvelle utilisation pharmaceutique |
| CA3112420A1 (en) * | 2018-09-14 | 2020-03-19 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates of montelukast and peptides |
| CN113613657A (zh) * | 2019-01-10 | 2021-11-05 | 江阴优培尔康药业有限公司 | 含有白三烯受体拮抗剂的新型配制品 |
-
2018
- 2018-07-04 KR KR1020207003363A patent/KR20200039677A/ko not_active Application Discontinuation
- 2018-07-04 CN CN202110903665.3A patent/CN113491696A/zh active Pending
- 2018-07-04 US US16/628,170 patent/US11672792B2/en active Active
- 2018-07-04 SG SG11201911841PA patent/SG11201911841PA/en unknown
- 2018-07-04 CN CN201880002883.6A patent/CN110312513B/zh active Active
- 2018-07-04 MX MX2020000029A patent/MX2020000029A/es unknown
- 2018-07-04 AU AU2018295944A patent/AU2018295944B2/en active Active
- 2018-07-04 CA CA3068818A patent/CA3068818A1/en active Pending
- 2018-07-04 MA MA052924A patent/MA52924A/fr unknown
- 2018-07-04 CN CN202210843681.2A patent/CN115300508A/zh active Pending
- 2018-07-04 WO PCT/CN2018/094441 patent/WO2019007356A1/en unknown
- 2018-07-04 EP EP18827979.8A patent/EP3648767A4/en active Pending
- 2018-07-04 JP JP2019572791A patent/JP7288404B2/ja active Active
- 2018-07-05 TW TW107123334A patent/TW201919633A/zh unknown
-
2023
- 2023-05-01 US US18/310,020 patent/US20230404992A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110312513B (zh) | 2022-07-08 |
| AU2018295944B2 (en) | 2023-12-14 |
| CN115300508A (zh) | 2022-11-08 |
| TW201919633A (zh) | 2019-06-01 |
| EP3648767A1 (en) | 2020-05-13 |
| CN110312513A (zh) | 2019-10-08 |
| WO2019007356A1 (en) | 2019-01-10 |
| MA52924A (fr) | 2021-04-28 |
| CN113491696A (zh) | 2021-10-12 |
| MX2020000029A (es) | 2020-08-06 |
| US20210145819A1 (en) | 2021-05-20 |
| JP2020527134A (ja) | 2020-09-03 |
| AU2018295944A1 (en) | 2020-02-20 |
| KR20200039677A (ko) | 2020-04-16 |
| JP7288404B2 (ja) | 2023-06-07 |
| US11672792B2 (en) | 2023-06-13 |
| CA3068818A1 (en) | 2019-01-10 |
| EP3648767A4 (en) | 2021-04-28 |
| US20230404992A1 (en) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201911841PA (en) | Topical formulations comprising montelukast and combinations with mussel adhesive proteins | |
| EP3480208A4 (en) | ANTIMICROBIAL PEPTIDE DERIVATIVE AND APPLICATION THEREOF | |
| EP3368555A4 (en) | DOUBLE FUNCTIONAL PROTEINS AND PHARMACEUTICAL COMPOSITION THEREFOR | |
| HK1257176A1 (zh) | 貽貝粘蛋白產品及其抑制粘膜炎症的應用 | |
| EP3255059A4 (en) | Antimicrobial peptide wy-21 and use thereof | |
| EP3453401A4 (en) | INTERLEUKIN COMBINATION AND THEIR USE | |
| EP3328994A4 (en) | CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF | |
| EP3369795A4 (en) | ADHESIVE COMPOSITION AND MELT ADHESIVE | |
| EP3444270A4 (en) | NEW NATURAL PROTEIN AND ITS APPLICATION | |
| EP3290441A4 (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
| EP3423076A4 (en) | TOPICAL FORMULATIONS CONTAINING CYCLOSPORINE AND USES THEREOF | |
| EP3553146A4 (en) | RESIN COMPOSITION AND USE THEREOF | |
| EP3312273A4 (en) | LABEL INDUCING DEGRADATION OF PROTEINS AND USE THEREOF | |
| EP3279209A4 (en) | Adhesive peptide and use therefor | |
| EP3684789A4 (en) | PROTEIN ENRICHED AND ZEINE DEPLETED | |
| EP3722305A4 (en) | HM-3 FUSION PROTEIN AND USES THEREOF | |
| EP3725799A4 (en) | PEPTIDE BONDED TO PL-L1 AND USES | |
| EP3667376A4 (en) | FLAT METAL LENS AND GLASS COVER INCLUDING IT | |
| EP3618577A4 (en) | COMPOSITION AND ELECTROLUMINESCENT ELEMENT INCLUDING IT | |
| EP3350276A4 (en) | ADHESIVE COMPOSITION AND ARTICLE MADE THEREFROM | |
| EP3378870A4 (en) | NOVEL ANTIMICROBIAL PEPTIDE AND USE THEREOF | |
| EP3290489A4 (en) | Silicone adhesive composition and adhesive tape | |
| EP3688472A4 (en) | CONJUGATED PROTEINS AND THEIR USES | |
| EP3585355A4 (en) | TOPICAL FORMULATIONS AND RELATED PROCESSES | |
| EP3489225A4 (en) | ANALOG OF VORTIOXETINE, ITS USE AND ITS PREPARATION |